secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unicycive Therapeutics, Inc. (UNCY)
CIK:        0001766140
Form:       8-K
Filed at:   2026-05-12T11:51:50+00:00
Accession:  0001213900-26-054736
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Unicycive Q1 2026 net loss $12.8M; OLC PDUFA target June 29, 2026
-----------------------------------------------------------------

- Net loss of $12.8M ($0.54 per share basic/diluted) vs net income of $0.5M in Q1 2025.
- Cash, cash equivalents & marketable securities $57.1M as of May 11, 2026; funds operations into 2027.
- FDA PDUFA target action date for oxylanthanum carbonate NDA resubmission is June 29, 2026.
- R&D expenses down to $1.6M (from $2.2M); G&A up to $6.8M (from $5.8M) year-over-year.
- Commercial readiness activities ongoing for potential OLC launch after PDUFA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1766140/000121390026054736/0001213900-26-054736-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1766140/000121390026054736/ea0290277-8k_unicycive.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-054736

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer